X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs DISHMAN PHARMA - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA DISHMAN PHARMA SUN PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x 28.9 25.1 115.2% View Chart
P/BV x 2.4 3.3 72.2% View Chart
Dividend Yield % 0.5 0.7 78.7%  

Financials

 SUN PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
DISHMAN PHARMA
Mar-16
SUN PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs701374 187.1%   
Low Rs433129 336.1%   
Sales per share (Unadj.) Rs110.4197.8 55.8%  
Earnings per share (Unadj.) Rs11.021.2 51.8%  
Cash flow per share (Unadj.) Rs17.234.7 49.6%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.40.8 44.4%  
Book value per share (Unadj.) Rs158.8179.9 88.3%  
Shares outstanding (eoy) m2,399.2680.69 2,973.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.11.3 403.6%   
Avg P/E ratio x51.611.9 435.1%  
P/CF ratio (eoy) x32.97.2 454.0%  
Price / Book Value ratio x3.61.4 255.2%  
Dividend payout %18.29.4 193.2%   
Avg Mkt Cap Rs m1,360,02120,306 6,697.7%   
No. of employees `00017.80.8 2,145.8%   
Total wages/salary Rs m53,6715,355 1,002.3%   
Avg. sales/employee Rs Th14,890.919,252.7 77.3%   
Avg. wages/employee Rs Th3,017.16,459.5 46.7%   
Avg. net profit/employee Rs Th1,480.62,064.1 71.7%   
INCOME DATA
Net Sales Rs m264,89515,961 1,659.7%  
Other income Rs m8,388265 3,160.4%   
Total revenues Rs m273,28216,226 1,684.2%   
Gross profit Rs m56,0814,103 1,366.8%  
Depreciation Rs m14,9981,091 1,375.2%   
Interest Rs m5,176944 548.0%   
Profit before tax Rs m44,2952,334 1,898.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,452624 1,355.3%   
Profit after tax Rs m26,3381,711 1,539.2%  
Gross profit margin %21.225.7 82.4%  
Effective tax rate %19.126.7 71.4%   
Net profit margin %9.910.7 92.7%  
BALANCE SHEET DATA
Current assets Rs m316,35911,018 2,871.3%   
Current liabilities Rs m198,6439,517 2,087.2%   
Net working cap to sales %44.49.4 472.6%  
Current ratio x1.61.2 137.6%  
Inventory Days Days95110 85.8%  
Debtors Days Days10835 309.1%  
Net fixed assets Rs m213,17816,304 1,307.5%   
Share capital Rs m2,399161 1,486.6%   
"Free" reserves Rs m378,60612,907 2,933.4%   
Net worth Rs m381,00614,516 2,624.8%   
Long term debt Rs m17,7214,189 423.0%   
Total assets Rs m643,02829,805 2,157.5%  
Interest coverage x9.63.5 275.4%   
Debt to equity ratio x00.3 16.1%  
Sales to assets ratio x0.40.5 76.9%   
Return on assets %4.98.9 55.0%  
Return on equity %6.911.8 58.6%  
Return on capital %10.017.5 57.2%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m40,8164,952 824.3%   
Fx outflow Rs m30,143697 4,326.0%   
Net fx Rs m10,6734,255 250.9%   
CASH FLOW
From Operations Rs m39,0722,786 1,402.2%  
From Investments Rs m-33,708-1,529 2,204.7%  
From Financial Activity Rs m-15,393-941 1,635.6%  
Net Cashflow Rs m-7,359316 -2,325.9%  

Share Holding

Indian Promoters % 63.7 61.4 103.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 3.7 138.6%  
FIIs % 23.0 12.7 181.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 22.1 37.6%  
Shareholders   133,026 46,261 287.6%  
Pledged promoter(s) holding % 0.5 35.8 1.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   ELDER PHARMA  FDC LTD.  SHASUN PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 491 Points Lower; Metal and Energy Stocks Witness Selling(Closing)

After opening the day marginally lower, share markets in India witnessed negative trading activity throughout the day and ended deep in the red.

Related Views on News

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)

Jun 6, 2019

Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)

Jun 10, 2019

The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jun 17, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS